Spatially resolved protein profiling in pancreatic adenosquamous carcinoma. Age, number of genomic alterations (GA) per tumor, and alteration frequency of select commonly altered genes based on TP53 ...

to investigate a p53 mutation called Y220C, which occurs in at least 30 cancer types and around 100,000 cancer patients every year. This mutation makes p53 'wobbly' - meaning it can't do its job of ...

An interesting concept of using SNAr chemistry to stabilize the Y220C mutant of p53 by turning the cysteine into a group that mimics the tyrosine conformation. https://lnkd.in/ejwaMeER ...

Genescience Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.

p53 is a transcription factor that regulates the expression of genes involved in tumor suppression. p53 mutations mediate tumorigenesis and occur in approximately 50% of human cancers. p53 regulates ...

A wonderful molecule by a wonderful team! FMC-220 delivers unprecedented potency and durable anti-tumor activity both in vitro and in vivo, achieving pronounced tumor regression at low doses!

The tumor suppressor p53 is activated upon multiple cellular stresses, including DNA damage, oncogene activation, ribosomal stress, and hypoxia, to induce cell cycle arrest, apoptosis, and senescence.

Background While p53 mutations occur early in Barrett’s oesophagus (BE) progression to oesophageal adenocarcinoma (EAC), their role in gastric cardia stem cells remains unclear. Objective This study ...